Form 4: Agenus Inc. CEO Garo Armen Receives Stock in Lieu of Cash Salary

Agenus Inc. CEO Garo H. Armen received 1,046 shares of common stock as payment for his salary for the pay period ending July 12, 2024, while also disposing of 76,661 shares.

Summary

• Garo H. Armen, CEO of Agenus Inc., received 1,046 shares of Agenus common stock on July 12, 2024, as compensation in lieu of cash salary.
• The stock was issued at a price of $15.60 per share, which was the closing price of Agenus common stock on that date.
• These shares were issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested upon issuance.
• Armen also disposed of 76,661 shares of common stock.
• Armen indirectly owns 31,298 shares through his IRA accounts and 28,950 shares as trustee and general partner.

Sentiment

Score: 6

Explanation: Neutral sentiment. The CEO taking stock in lieu of cash is a positive signal, but the disposal of a significant number of shares introduces uncertainty.

Positives

• The CEO's decision to receive salary in stock demonstrates confidence in the company's future performance.
• The stock was issued under the company's equity incentive plan, aligning the CEO's interests with those of shareholders.

Negatives

• The disposal of 76,661 shares by Armen could be interpreted negatively by investors, although the reason for the disposal is not specified.

Risks

• The Form 4 filing does not provide detailed context for the disposal of 76,661 shares, which could lead to investor uncertainty.
• Reliance on stock-based compensation may dilute existing shareholders if not managed carefully.

Future Outlook

The document does not contain specific forward-looking statements or guidance.

Management Comments

• At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash.

Industry Context

Stock-based compensation is a common practice in the biotechnology industry to conserve cash and align executive incentives with shareholder value. The CEO taking stock in lieu of cash is a positive signal.

Comparison to Industry Standards

• Many biotech companies, such as Amgen and Gilead, use stock options and restricted stock units as part of their executive compensation packages.
• The specific amount and terms of stock-based compensation vary widely based on company size, performance, and industry norms.
• Compared to companies like Regeneron, which also uses stock options extensively, Agenus's approach appears consistent with industry practices for incentivizing leadership.

Stakeholder Impact

• Shareholders may view the CEO's acceptance of stock in lieu of cash as a positive sign of confidence.
• Employees may see this as a commitment from leadership to the company's long-term success.

Key Dates